enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 16,000 shares, a growth of 400.0% from the February 29th total of 3,200 shares. Based on an average trading volume of 39,600 shares, the short-interest ratio is currently 0.4 days.

enGene Trading Down 8.2 %

NASDAQ ENGNW opened at $5.25 on Thursday. enGene has a 1-year low of $0.39 and a 1-year high of $6.50. The company’s fifty day moving average price is $3.09.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.